Keywords: par, ortho-mcneil, resolve, ultracet, patent, dispute, usa
Par and Ortho-McNeil resolve Ultracet patent dispute
Article | 30 July 2007
The USA's Par Pharmaceutical has entered into a settlement and license agreement with Johnson & Johnson unit Ortho-McNeil that resolves a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
